Lumos slides as height growth drug underperforms existing hormone therapy in trial

Lumos Pharma

14/11/2022 19:12

** Shares of Lumos Pharma  LUMO.O  falls 21.4% to $7 in
afternoon trade
    ** All doses of co's oral drug LUM-201 shows lower increase
in height compared to recombinant human growth hormone (rhGH) in
mid-stage trials for treatment of pediatric growth hormone
deficiency 
    ** Data shows annualized height velocity of up to 8.6 cm per
year at 6 months for the drug vs 11.05 cm/year increase through
rhGH treatment - co
    ** Co adds the study is 80% enrolled till date, on track to
report full study results in H2 2023
     ** Brokerage Jones Research says co's LUM-201
"underperforms" rhGH treatment at all doses, but expects this
gap to narrow as trial size increases
    ** Including session's loss, stock nearly flat YTD
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))